Earnings
Home›Earnings›Previews›ARS Pharma trims spending while pushing neffy market s…
ARS Pharma trims spending while pushing neffy market share
Neffy’s total US share rose to 5% in the second quarter, and the company is guiding to more than a 40% drop in cash SG&A in the back half of 2026.
ARS Pharmaceuticals, Inc. said it is cutting spending as it pursues growth for neffy, its intranasal epinephrine for allergic reactions. The company discussed the plan during its second-quarter 2026 earnings call on August 13, the first for new President and CEO Donn Casale.
ARS reported that neffy’s total US share reached 5% in the second quarter, up from 2.5% a year earlier. Within the sales team’s targeted call universe, share climbed to 8% from 4%, and the company said it logged more than 16,000 unique neffy prescribers in the quarter.
Casale said the push reflects a gap between covered and uncovered territory, with 8% share where sales are active versus about 1% where they are not. ARS also said it brought in Meg Smith as Chief Commercial Officer, and that the field organization is focused on highest-value prescribers that represent 44% of the total market opportunity.
Alongside the neffy push, ARS is extending its intranasal epinephrine platform into chronic spontaneous urticaria, a market the company said has no FDA-approved on-demand treatment for acute flares. On costs, the company reported second-quarter total revenue of $33.7 million, with operating expenses of $95.1 million, and it now expects combined SG&A and R&D of $114 million to $126 million in the back half of 2026, with cash-based spending in that category projected at $100 million to $110 million, a reduction of more than 40% in cash SG&A versus the first half of 2026.